Piperazinylcarbonylquinolines and -isoquinolines
CA 2434773 C · Owner: Seyfried, Christoph · Inventors: Bartoszyk, Gerd; Seyfried, Christoph; Bottcher, Henning
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound of formula I, (see formula I) in which: R1 is a phenyl radical which is unsubstituted or substituted by R3 and/or , R4; R2 is a quinolinyl or isoquinolinyl radical; R3 is H; R4 is Hal; alk is ethylene; and , Hal is F, Cl, Br or I; or a physiologically acceptable salt thereof is a potent 5-HT2A , antagonist and is suitable for the treatment of psychoses schizophrenia, depression, neurological disorders memory disorders, Parkinson's disease, amyotrophic lateral sclerosis Alzheimer's disease, Huntington's disease eating , disorders, such as bulimia, anorexia nervosa premenstrual syndrome and/or for , positively influencing obsessive-compulsive disorder (OCD).
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 24, 2001 and granted October 4, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 24, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 24, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.